{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T20:17:22Z","timestamp":1780431442528,"version":"3.54.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National key Research and Development Program of China","doi-asserted-by":"publisher","award":["2016YFC0901504"],"award-info":[{"award-number":["2016YFC0901504"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","jocn-journal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.jocn.2019.04.003","type":"journal-article","created":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T16:42:30Z","timestamp":1557333750000},"page":"41-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Clinical characteristics and long term follow-up of Lambert-Eaton myasthenia syndrome in patients with and without small cell lung cancer"],"prefix":"10.1016","volume":"65","author":[{"given":"Yiqi","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyue","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongbo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2019.04.003_b0005","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S1474-4422(11)70245-9","article-title":"Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies","volume":"10","author":"Titulaer","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jocn.2019.04.003_b0010","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0035-3787(04)70888-7","article-title":"Lambert-Eaton myasthenic syndrome","volume":"160","author":"Newsom-Davis","year":"2004","journal-title":"Rev Neurol"},{"key":"10.1016\/j.jocn.2019.04.003_b0015","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/ana.10392","article-title":"Reduction of P\/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert-Eaton myasthenic syndrome","volume":"53","author":"Fukuda","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jocn.2019.04.003_b0020","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s00415-003-1063-7","article-title":"The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland","volume":"250","author":"Wirtz","year":"2003","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2019.04.003_b0025","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJM199506013322203","article-title":"Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes","volume":"332","author":"Lennon","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2019.04.003_b0030","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0022-510X(96)05303-8","article-title":"Incidence of serum anti-P\/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome","volume":"147","author":"Motomura","year":"1997","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jocn.2019.04.003_b0035","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/mus.20389","article-title":"Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome","volume":"32","author":"Oh","year":"2005","journal-title":"Muscle Nerve"},{"issue":"Pt 3","key":"10.1016\/j.jocn.2019.04.003_b0040","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/brain\/111.3.577","article-title":"The Lambert-Eaton myasthenic syndrome. A review of 50 cases","volume":"111","author":"O\u2019Neill","year":"1988","journal-title":"Brain"},{"key":"10.1016\/j.jocn.2019.04.003_b0045","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/j.1749-6632.1998.tb11024.x","article-title":"Lambert-Eaton myasthenic syndrome (LEMS). Clinical and electrodiagnostic features and response to therapy in 59 patients","volume":"841","author":"Tim","year":"1998","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jocn.2019.04.003_b0050","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40120-015-0034-0","article-title":"The European LEMS registry: baseline demographics and treatment approaches","volume":"4","author":"Mantegazza","year":"2015","journal-title":"Neurol Ther"},{"key":"10.1016\/j.jocn.2019.04.003_b0055","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1212\/01.WNL.0000037485.56217.5F","article-title":"Seronegative Lambert-Eaton myasthenic syndrome: study of 110 Japanese patients","volume":"59","author":"Nakao","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2019.04.003_b0060","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jneuroim.2008.05.025","article-title":"The Lambert-Eaton myasthenic syndrome 1988\u20132008: a clinical picture in 97 patients","volume":"201\u2013202","author":"Titulaer","year":"2008","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jocn.2019.04.003_b0065","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1200\/JCO.2010.32.0440","article-title":"Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS","volume":"29","author":"Titulaer","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jocn.2019.04.003_b0070","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jneuroim.2017.05.021","article-title":"Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis","volume":"311","author":"Jing","year":"2017","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jocn.2019.04.003_b0075","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/ana.10477","article-title":"Oculobulbar involvement is typical with Lambert-Eaton myasthenic syndrome","volume":"53","author":"Burns","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jocn.2019.04.003_b0080","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1136\/jnnp.73.6.766","article-title":"Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome","volume":"73","author":"Wirtz","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jocn.2019.04.003_b0085","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/mus.25520","article-title":"Lambert-Eaton myasthenic syndrome: epidemiology and therapeutic response in the national veterans affairs population","volume":"56","author":"Abenroth","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jocn.2019.04.003_b0090","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(05)76153-5","article-title":"Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma","volume":"353","author":"Maddison","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jocn.2019.04.003_b0095","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jneuroim.2005.04.001","article-title":"P\/Q-type calcium channel antibodies, Lambert-Eaton myasthenic syndrome and survival in small cell lung cancer","volume":"164","author":"Wirtz","year":"2005","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jocn.2019.04.003_b0100","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.lungcan.2017.11.022","article-title":"Characterization of never-smoking and its association with clinical outcomes in Chinese patients with small-cell lung cancer","volume":"115","author":"Liu","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jocn.2019.04.003_b0105","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1007\/s11596-016-1684-6","article-title":"Clinical features and prognostic factors of small cell lung cancer: a retrospective study in 148 patients","volume":"36","author":"Cai","year":"2016","journal-title":"J Huazhong Univ Sci Technol Med Sci"},{"key":"10.1016\/j.jocn.2019.04.003_b0110","first-page":"11033","article-title":"The prognostic factors in the elderly patients with small cell lung cancer: a retrospective analysis from a single cancer institute","volume":"8","author":"Liu","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.jocn.2019.04.003_b0115","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1212\/WNL.0000000000003794","article-title":"Long-term survival in paraneoplastic Lambert-Eaton myasthenic syndrome","volume":"88","author":"Maddison","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2019.04.003_b0120","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1016\/j.clinph.2014.06.031","article-title":"Lambert-Eaton myasthenic syndrome - diagnosis, pathogenesis and therapy","volume":"125","author":"Hulsbrink","year":"2014","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/j.jocn.2019.04.003_b0125","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/clpt.2009.35","article-title":"Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study","volume":"86","author":"Wirtz","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jocn.2019.04.003_b0130","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/jnnp.2009.197632","article-title":"The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome","volume":"82","author":"Maddison","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586818311871?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586818311871?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T20:38:30Z","timestamp":1565123910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586818311871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":26,"alternative-id":["S0967586818311871"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2019.04.003","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical characteristics and long term follow-up of Lambert-Eaton myasthenia syndrome in patients with and without small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2019.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}